Curing Cancer with Proton Beams

 

Particle accelerators do more than just particle physics research. Suzie Sheehy takes a look at the history and promise of proton therapy: using particle accelerators to fight cancer.

The discovery of X-rays in 1895 was the start of the first breakthrough in modern cancer treatment. Wilhelm Röntgen used a cathode ray tube to generate X-rays. It didn’t take long for the destructive power of these rays to be turned to medicinal benefit. X-rays kill cancer cells through ionization. By stripping electrons from water molecules, the X-ray photons leave a highly chemically reactive wake. The reactive water molecules bind to, and destroy, DNA.

But X-ray beams don’t differentiate between healthy and cancerous cells, so their destructive force is hard to localize to the problem zones alone. One option is to use protons, rather than X-ray photons. Particle accelerators can take protons from inside a Hydrogen atom, form them into high energy beams and more specifically target a tumour.

However, instead of passing through the body like X-ray photons, the protons stop at the tumour, thanks to a phenomenon called the ‘Bragg peak’. By tuning the energy of a proton beam, the dose can be much more carefully controlled.

Click to view all articles for the EPIC:
Or click to view the full company profile:
    Share on facebook
    Facebook
    Share on twitter
    Twitter
    Share on linkedin
    LinkedIn
    Advanced Oncotherapy Plc

    More articles like this

    Hardman & Co

    Advanced Oncotherapy: Leveraging the modularity of LIGHT

    Advanced Oncotherapy plc (LON:AVO) goal is to deliver an affordable and novel PT system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, important technical milestones have significantly de-risked the

    Hardman & Co

    Advanced Oncotherapy funded through to clinical events

    AVO’s goal is to deliver an affordable and novel proton therapy (PT) system, called LIGHT, based on state-of-the-art technology developed originally at the world-renowned CERN. Over the past two years, the project has been significantly de-risked through important

    Hardman & Co

    Advanced Oncotherapy Rapidly changing to commercial execution

    Advanced Oncotherapy plc (LON:AVO) is the topic of discussion when Dr Martin Hall Analyst at Hardman & Co joins DirectorsTalk. Martin talks us through the interesting developments being made at the company, commercial deals, brings us up to date

    Hardman & Co

    Advanced Oncotherapy Confidence in LIGHT gaining momentum

    The Advanced Oncotherapy PLC (LON:AVO) goal is to deliver an affordable and novel proton beam therapy (PBT) system, based on state-of-the-art technology developed originally at the world-renowned CERN. In the past 18 months, the project has been de-risked